Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies.
Soulard M, Galicier L, Mahlaoui N, Fieschi C, Deshayes S, Gobert D, Gourguechon C, Henique H, Humbert S, Lacout C, Le Calloch R, Michel M, Piel-Julian ML, Viallard JF, Lescoat A, Godeau B, Perlat A.
Soulard M, et al. Among authors: piel julian ml.
Blood Adv. 2024 Sep 30:bloodadvances.2024014370. doi: 10.1182/bloodadvances.2024014370. Online ahead of print.
Blood Adv. 2024.
PMID: 39348667